loader2
Login Open ICICI 3-in-1 Account

Natco Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Natco Pharma Ltd. 14 Nov 2025 14:05 PM

Q2FY26 Quarterly Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q2FY26 results

  • Consolidated total revenue of Rs 1,463.0 crore for Q2FY26 as against Rs 1,434.9 crore as of 30th September 2024.
  • EBITDA (including other income) for the quarter was at Rs 679.2 crore with margins at 46.4%.
  • The net profit for the period, on a consolidated basis was Rs 517.9 crore.
  • The Board of Directors have declared an interim dividend of Rs 1.5 per equity share of Rs 2 each during Q2FY26.

Result PDF

Pharmaceuticals company Natco Pharma announced Q1FY26 results

  • Consolidated total revenue of Rs 1,390.6 crore for Q1FY26 as against Rs 1,410.7 crore as Q1FY25.
  • EBITDA for the quarter was at Rs 632.7 crore with margins at 45.5%.
  • Net profit for the period, on a consolidated basis was Rs 480.3 crore.
  • The Board of Directors have declared an interim dividend of Rs 2 per equity share of Rs 2 each during Q1FY26.

Result PDF

Pharmaceuticals company Natco Pharma announced Q3FY25 results

  • NATCO recorded consolidated total revenue of Rs 651.1 crore for Q3FY25, as against Rs 795.6 crore for Q3FY24.
  • The net profit for the period, on a consolidated basis, was Rs 132.4 crore as against Rs 212.7 crore for Q3FY24.
  • The Board of Directors has declared third interim dividend of Rs 1.5 per equity share, for FY25.

Result PDF

Pharmaceuticals company Natco Pharma announced Q2FY25 results

  • Consolidated total revenue of Rs 1434.9 crore for the Q2FY25 as against Rs 1060.8 crore for the Q2FY24, reflecting a growth of 35.3%.
  • Net profit for the period, on a consolidated basis, was Rs 676.5 crore as against Rs 369.0 crore Q2FY24, showing robust growth of about 83%.
  • The Board of Directors has declared second interim dividend of Rs 1.50 per equity share, for FY25.

Result PDF

Pharmaceuticals company Natco Pharma announced Q4FY24 & FY24 results:

  • Q4FY24: Total Revenue stood at Rs 11,103 million
  • Pharma Export Formulations at Rs 9,549 million
  • Consolidated Total Revenue for FY24 stood at Rs 41,269 million
  • Earnings Before Interest Tax Depreciation and Amortization stood at Rs 5,393 million for Q4FY24 and Rs 18,795 million for FY24
  • EBITDA Margin for Q4FY24 & FY24 was at 48.6% and 45.5% respectively
  • Profit Before Tax for Q4FY24 at Rs 4,776 million and Rs 16,735 million for FY24
  • Basic and Diluted EPS for FY24 is Rs 77.34 per share
  • Profit after tax for Q4FY24 was at Rs 3,863 million
  • Net Profit for FY24 was at Rs 13,883 million
  • EBITDA and EBITDA Margin includes other income Investment of USD 2 million in Cellogen Therapeutics Private Ltd., with R&D programs involving Cell and Gene Therapy Solutions

Result PDF

Pharmaceuticals company Natco Pharma announced Q1FY24 results:

  • Consolidated total revenue of Rs 1,160.2 crore for Q1FY24, as against Rs 918.9 crore for Q1FY23, a growth of 26.3%.
  • The net profit for Q1FY24, on a consolidated basis, was Rs 420.3 crore as against Rs 320.4 crore in Q1FY23, showing 31.2% growth.
  • The company had made a provision of Rs 51.0 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentives to employees.
  • The Board of Directors has declared an interim dividend of Rs 7/- (350%) per equity share of Rs 2/- each, for the FY24.

 

 

Result PDF

Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results:

  • Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth.
  • The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22.
  • The increase in revenue and profits for FY23 was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years.
  • For Q4FY23, the company recorded a net revenue of Rs 926.9 crore, on a consolidated basis, as against Rs 610.6 crore during Q4FY22.
  • The profit for Q4FY23 on a consolidated basis was Rs 275.8 crore, as against a loss of Rs 50.5 crore in Q4FY22.

 

 

Result PDF

Natco Pharma announced Q3FY23 results:

  • Consolidated Q3FY23:
    • Total revenue of Rs 513.3 crore, for the Q3FY23, as against Rs 590.7 crore for the same period last year that had a one-time licensing revenue.
    • The net profit for the period was Rs 62.3 crore as against Rs 80.4 crore last year.
  • Consolidated 9MFY23:
    • The company recorded total revenue of Rs 1,884.8 crores against Rs 1,433.2 crore for same period last year and on the net profit side, the company recorded Rs 439.5 crore as against Rs 220.5 crore
  • The Board of Directors has declared 3rd Interim dividend of Rs 1.25 per eqully share, for FY23.

Result PDF

Natco Pharma announced Q3FY23 results:

  • Consolidated Q3FY23:
    • Total revenue of Rs 513.3 crore, for the Q3FY23, as against Rs 590.7 crore for the same period last year that had a one-time licensing revenue.
    • The net profit for the period was Rs 62.3 crore as against Rs 80.4 crore last year.
  • Consolidated 9MFY23:
    • The company recorded total revenue of Rs 1,884.8 crores against Rs 1,433.2 crore for same period last year and on the net profit side, the company recorded Rs 439.5 crore as against Rs 220.5 crore.
  • The Board of Directors has declared 3rd interim dividend of Rs 1.25 per equity share, for FY23.

Result PDF

Natco Pharma declares Q4FY22 result:

  • NATCO Pharma has recorded consolidated total revenue of INR 2043.8 Crore for the year ended on 31st March, 2022, as against INR 2155.7 Crore for the last year. The net profit for the period, on a consolidated basis, was INR 170.0 Crore, as against INR 442.4 Crore last year.
  • The reduction in the profit was primarily due to inventory value write-off and provision of receivables related to Covid products, with inventory value write-off of INR 232.0 Crore and provision of INR 46.0 Crore towards estimated credit loss. Export business performed well during the quarter driven by Lenalidomide sales and profit.
  • For the fourth quarter (Q4) ended March 31st, 2022, the company recorded net revenue of INR 610.6 Crore, on a consolidated basis, as against INR 359.7 Crore during Q4, FY 2021. There was a loss for the fourth quarter period, on a consolidated basis, of INR 50.5 Crore, primarily due to inventory value write-off and provision of estimated credit losses, as against a profit of INR 53.0 Crore same quarter last year.

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app